Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar;4(5):94.
doi: 10.21037/atm.2015.12.46.

Radiotherapy: killing with complement

Jean F Regal  1 , Kenneth J Dornfeld  1 , Sherry D Fleming  1
Affiliations

Radiotherapy: killing with complement

Jean F Regal et al. Ann Transl Med. 2016 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Radiation-induced complement activation initiates adaptive immune response and tumor cell death. The study of Surace et al. (1) demonstrates that radiotherapy induces cell necrosis, increases local production of C3 within the tumor and a transient local increase in complement activation with C3a and C5a generation. Increased complement activation results in C3 deposition on tumor cells. C3a and/or C5a are critically important for stimulation of dendritic cell maturation and interferon production by cytotoxic CD8+ T cells leading to a beneficial clinical response and tumor cell killing. Orange symbols represent activation of the innate immune response while green symbols represent activation of the adaptive immune response. Solid arrows represent data within the Surace et al. manuscript, while dashed arrows represent implied actions consistent with literature and existing data.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Surace L, Lysenko V, Fontana AO, et al. Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response. Immunity 2015;42:767-77. 10.1016/j.immuni.2015.03.009 - DOI - PubMed
    1. Klos A, Wende E, Wareham KJ, et al. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol Rev 2013;65:500-43. 10.1124/pr.111.005223 - DOI - PubMed
    1. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003;300:1155-9. 10.1126/science.1082504 - DOI - PubMed
    1. Rao SS, Thompson C, Cheng J, et al. Axitinib sensitization of high Single Dose Radiotherapy. Radiother Oncol 2014;111:88-93. 10.1016/j.radonc.2014.02.010 - DOI - PMC - PubMed
    1. Bode GH, Losen M, Buurman WA, et al. Complement activation by ceramide transporter proteins. J Immunol 2014;192:1154-61. 10.4049/jimmunol.1301673 - DOI - PubMed

LinkOut - more resources